ArticleFrontiers in immunology2025
Comprehensive analysis based on the ubiquitination- and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a highly invasive gastrointestinal malignancy, esophageal squamous cell carcinoma (ESCC) carries with its high morbidity and mortality. Accumulating evidence indicates that abnormal activation of ubiquitination and deubiquitylation has been implicated in pathophysiology of ESCC. However, rare prognostic models for ubiquitination-related genes (URGs) and deubiquitylation-related genes (DRGs) have been built up in ESCC. Methods: From training dataset GSE53624, the differentially expressed prognostic URGs and DRGs were identified to develop a prognostic signature, which was validated in GSE53622 and TCGA-ESCC dataset to show the robustness of the signature. To further confirm their prognosis value, the unsupervised clustering analysis was used to develop the molecular subtypes based on the prognostic URGs and DRGs. Differences in terms of biological function, immune status, and drug sensitivity were evaluated between high- and low-risk groups. The nomogram was constructed by combining the URGs and DRGs prognostic signature and clinical characteristics to improve prediction efficacy. Loss-of-function studies were conducted to explore the biological function of NEURL3 in ESCC. Results: The URGs and DRGs prognostic signature consisted of 11 genes and exhibited high accuracy in predicting prognosis of ESCC patient. Based on these 11 URGs and DRGs, two molecular subtypes of ESCC (C1 and C2) were identified, of which C2 subtype had significantly shorter overall survival time than that of C1 subtype. The function enrichment analysis showed that these genes play key roles in essential processes such as tumor metastasis and immune response. Moreover, the risk score was closely related to infiltration abundance of some types of immune cells, gene markers of immune cells and immune checkpoint-related markers. The drug sensitivity analysis showed that dacomitinib and talazoparib may serve as anti-ESCC drugs through targeting MAPK14. The nomogram was established by combining the URGs and DRGs signature with age and TNM stage, and it also showed enhanced prognostic predictive accuracy. The Conclusions: Based on the URGs and DRGs prognostic signature, a novel nomogram was constructed that could serve as a potentially reliable prognostic model and provide theoretical basis for uncovering potential therapeutic target in the treatment of ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.